Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In previous pharmacological experiments with the choleretic agent Febuprol, healthy subjects showed a significant increase in bile flow and its constituents in the acute experiment. As a consequence of these results we have carried out a double-blind cross-over therapeutic trial with Febuprol in 50 patients with a cholecystopathic symptom complex. After a 14 days' treatment (3 capsules daily) a significant improvement of the typical symptoms (feeling of fullness, pressure in the upper abdomen, meteorism, constipation, flatulence and nausea after food) was recorded in these patients. Moreover a significant lowering of the serum cholesterol level was noteworthy.
 ...
PMID:[Clinical studies on the choleretic agent Febuprol (author's transl)]. 34 24

A double blind trial was performed in patients with Cesarean section in order to study the effect of Simeticon (Stuart Pharmaceutical Company, Pasadena, California) on the occurrence of subjective and objective signs of gas distress during the immediate postoperative period. The results obtained with Simeticon show a highly significant reduction of the analysed subjective complaints (nausea, vomiting, meteorism, discomfort in the stomach, abdominal pains) in relation to placebo. Peristaltic movements in patients treated with Simeticon appeared in the first two days in 100% of cases and only in 30% in the placebo group. Flatulence also appeared in all the patients receiving Simeticon, in contrast to only 20% in the placebo group. There was no difference in spontanous defecation between the groups. On the basis of the results obtained, and considering the non-toxicity of the drug, its chemical inertnees, good tolerance, and simple use, the authors consider simeticon very useful for the prevention and therapy of postoperative discomfort due to gas accumulation and gastro-intestinal distention after Cesarean section.
 ...
PMID:[Use of simethicone in the prevention of postoperative abdominal discomfort and gastrointestinal distension after cesarean section]. 39 87

Abdominal pain, nausea, flatulence and diarrhea are the main clinical symptoms in chronic amebiasis; diarrhea and constipation may alternate in many cases, whereas constipation alone does occur only rarely. These symptoms may persist over years, with long asymptomatic intervals. In most cases cysts of entameba histolytica can be demonstrated in the feces, accompanied rather often by dientameba fragilis in Israel. 835 carriers of entameba histolytica were found among our patients between 1968 and 1974. Patients exhibiting 3 of the above mentioned clinical symptoms and having entameba histolytica in the stools are defined to be suffering from chronic recurrent amebiasis; 371 (= 44%) of our patients could be classified in this group. In spite of the fact, that the number of cases of acute amebiasis and its complications in Israel has been reduced considerably in the past, chronic amebiasis continues to be a clinical and epidemiological problem, its incidence being scarcely diminished.
 ...
PMID:[Chronic recurrent intestinal amebiasis in Israel (author's transl)]. 49 12

The indication field of Nortase, a combination of microbial lipolytic and proteolytic enzymes, comprises the replacement therapy of maldigestion and insufficiency of pancreas. Its efficacy and tolerance were tested in 100 patients in an open study under the conditions of general practice. During the 15-day treatment the following symptoms were evaluated: anorexia, flatulence, pressure and pain in the epigastrium, nausea after the meals, belching, pyrosis, the quality of feces and the body weight. 96% of the patients showed relief of the symptoms after treatment, 65% a therapeutic result ranging from very good to good. In 53% an improvement of the quality of feces was observed and 76% reached an increase in weight. 6 patients had some small side effects, in 1 case the treatment had to be interrupted. The altogether good results confirmed the results of former investigations on the acid stability and the high lipolytic activity of lipase from Rhizopus arrhizus.
 ...
PMID:[Experiences with substitution therapy using a new pancreatic enzyme of plant origin]. 70 May 83

The controversy about gallbladder polyps has centered chiefly around their potential for malignancy. Among 3,525 cholecystectomies done over a 25-year period, there were 26 cases of carcinoma with only 9% not associated with stones. Thirty-nine cases of polypoid lesions of the acalculous gallbladder were investigated. The classic symptoms of pain, flatulence, food intolerance, and nausea were present in the great majority of cases. Most patients, especially those with symptoms of short duration, reported improvement following cholecystectomy.
 ...
PMID:Polypoid lesions of the acalculous gallbladder. 80 59

The main symptoms of infection with Giardia intestinalis in 33 Sudanese adults were abdominal pain, flatulence and diarrhoea. Other symptoms were offensive stools, loss of weight, milk intolerance, mucoid stools, nausea and vomiting. Tinidazole given orally as 150 mg. twice daily dose for seven days or as a single 1,000 mg. dose, eradicated the infection in 32 out of the 33 patients. This parasitological cure was obtained in all 21 patients who received the seven day course and in 11 out of 12 patients who were given the single dose. All symptoms disappeared in 16 out of the 32 patients and in the remaining half improvement was marked particularly as regards the three main symptoms of the disease. The single dose gave no side effects but nausea, headache, skin rash and worsening of abdominal pain and diarrhoea occurred in some patients who received the seven day treatment course.
 ...
PMID:Symptomatic giardiasis in Sudanese adults and its treatment with tinidazole. 85 Feb 86

Report is made about 15 patients suffering from most serious adiposity; owing to complete inefficiency of conservative methods of therapy whatsoever, a shunt operation of the small intestine according to Payne Dewind, modified after Baden, was carried out in these patients. After a period of observation, weight decrease amounted to 40 to 50 p.c. of the starting weight. Side effects having manifested immediately after operation, such as weariness, giddy sensations, nausea, flatulence, sweating stages, etc., disappeared after about six months. The highly increased frequency of stools was reduced--after two years--to one to two defectations per day. Increased blood pressure values returned to normal.
 ...
PMID:[Shunt operations of the small intestine in cases of extreme adiposity (author's transl)]. 85 34

Acarbose, an alpha-glucosidase inhibitor, delays absorption of carbohydrate in the gut, thereby lowering postprandial glucose levels. Safety data on this drug have been gathered in a series of studies on animals and in extensive clinical trials in humans. Although an initial long term feeding study in rats showed an excess of renal tumours at very high dosages of acarbose (up to 300 mg/kg bodyweight daily), further evaluation with similar studies in rats, hamsters, and dogs indicated that the problem was related to carbohydrate malabsorption. With adequate glucose intake and in gavage studies, no difference in tumour incidence between placebo- and acarbose-treated groups was seen. From 1976 to 1989, safety data on acarbose were obtained in approximately 8800 patients in 2 separate groups of clinical trials, the Bayer International Clinical Data Pool and the American phase III trials. Almost all adverse experiences, as reported by 56 to 76% of patients on acarbose vs 32 to 37% of patients on placebo, were related to the digestive system and included diarrhoea, flatulence, bloating and nausea. Most symptoms were of mild to moderate intensity and tended to improve with time. In the American trials a small but significant increase in liver transaminases was seen, 3.8% in acarbose-treated patients vs 0.9% in controls together with a 1% increase in anaemia in the acarbose group. Overall, acarbose was well tolerated and the adverse experience profile was clinically acceptable.
 ...
PMID:Safety profile of acarbose, an alpha-glucosidase inhibitor. 128 May 77

This study examined the relationship between gastrointestinal (GI) symptoms and dietary intake in triathletes. Fifty-five male triathletes (age 31 +/- 6 yrs) were surveyed regarding the most recently completed half Iron Man triathlon. Questions were asked regarding GI symptoms and dietary intake. Fifty-two percent complained of eructation and 48% of flatulence. Other symptoms were abdominal bloating, vomiting urge, vomiting, nausea, stomachache, intestinal cramps, and diarrhea. More symptoms occurred while running than at other times. All individuals who had eaten within 30 min of the start vomited while swimming. Fat and protein intake was greater in those who vomited or had the urge to vomit than in those without these symptoms. Of the former, 93% had consumed a hypertonic beverage. Forty percent of those who drank a hypertonic beverage and only 11% of those who drank an iso- or hypotonic beverage had severe complaints. Four of five individuals with stomachache had consumed a strongly hypertonic beverage. All subjects with intestinal cramps had eaten fiber-rich foods in the prerace meal; only 10% of those without cramps had done so.
 ...
PMID:Gastrointestinal complaints in relation to dietary intake in triathletes. 133 83

The safety and efficacy of patient-controlled analgesia used for postoperative pain relief were evaluated. Cumulative 24-hour requirements were analyzed for possible correlation with patient characteristics. All patients who used a patient-controlled analgesia device for postoperative pain relief were reviewed from June to October 1991. The device Baxter's basal/bolus infusor with patient control module, was used to deliver fentanyl in 379 patients. The fentanyl requirement, verbal analog pain score, first passage of flatus, side effects, sedative score, and degree of satisfaction were examined. The fentanyl requirement during the first 24 hours after operation was analyzed with regard to age, body weight, and sex. The daily fentanyl consumption in the first three postoperative days was 928 +/- 352 micrograms (n = 338), 553 +/- 259 micrograms (n = 220), and 490 +/- 222 micrograms (n = 71), respectively. The requirement for fentanyl during the first 24 hours after surgery was significantly higher than for the next two days (p-value < 0.001). Fentanyl consumption correlated well with body weight, and inversely with age. No difference was found between fentanyl consumption and sex (p-value = 0.4687). The mean time to the first passage of flatus in patients with abdominal surgery was 54.6 +/- 26.4 hours. The incidence of nausea, vomiting, and dizziness was similar, about 20% of patients. Itching was noted in 7% of patients. Oversedation (class 4) was found in three patients during the first operative day, the sedative score for other patients were around class 1-3. No patient exhibited signs of respiratory depression or withdrawal syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[The efficacy of intravenous fentanyl patient-controlled analgesia for postoperative pain relief]. 134 40


1 2 3 4 5 6 7 8 9 10 Next >>